Lymphoma Clinical Trials

Showing 2141-2160 of 3,379 trials

Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

NCT03120676

This is a study with the purpose of studying the safety and efficacy of the study drug Atezolizumab in patients with relapsed or refractory Hodgkin lymphoma (HL). Atezolizumab could shrink cancer but it could also cause side effects. This study will also test any good and bad effects the study drug. Other aims include studying biomarkers that will help researchers understand how the drug works.

Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center3 participantsStarted Apr 2017

Basking Ridge, New Jersey, United States • Middletown, New Jersey, United States • Commack, New York, United States +3 more locations

COMPLETEDPhase 4

Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)

NCT01007448

This is a multicenter, randomized, open-label, Phase IV study to assess the efficacy, tolerability, and safety of 2 initial dose levels of bexarotene capsules in participants with refractory CTCL.

Refractory Cutaneous T-cell Lymphoma

Bausch Health Americas, Inc.59 participantsStarted Jan 2010

Birmingham, Alabama, United States • Miami, Florida, United States • Atlanta, Georgia, United States +14 more locations

Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)

Related Searches

Applying PET/MR in Oncology - a Prospective Project

Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma

Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA

CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin

Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL

A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma

Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation

Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma

Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients